FY2022 Q3 Financial and R&D Update

Other Initiatives in Each Region JPN Europe/ ASCA Anticancer agent EZHARMIAⓇ launched in Dec. 2022 ➤ Indication: Relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) ➤ MOA: Dual EZH1 and EZH2* inhibitor ➤ Administration: Usually, dosage for adult is 200 mg of valemetostat orally administered once daily on an empty stomach. The dose should be reduced as appropriate according to the patient's condition *Histone methyltransferase involved in hematological cancer progression 0 ·抗限性場剂 EZHI/2關書「エザルミア錠50mg バレメトスタットトシル -> 50mg 抗燃性寫潮 EZHI/2黑 Daiichi-Sankyo 10錠 10% バレメトスタットトシル酸塩錠「エザルミア錠100mg 100mg EZHARMIAⓇ Tablet 50mg, 100mg Agreement with Kite Pharma, Inc.: MA Transfer of Human Cell Therapy Product YESCARTAⓇ R ➤ Objective: Expansion of access to YESCARTA ® therapy ➤ Transfer to: Gilead Sciences, K.K. (an affiliate of Kite Pharma, Inc.) Timing: In CY 2023 ➤Financials: DS to receive a royalty on product sales and a sales milestone payment CLEAR Outcomes trial of lipid-lowering treatment NILEMDOⓇ met the primary study endpoint. The trial has been designed to evaluate if bempedoic acid reduces CV events in high- and very high-risk patients who tolerate no or very low doses of statin (Jan. 2023) CLEAR Outcomes study ➤ event-driven, randomized, multicenter, double-blind, placebo-controlled Ph3 study led by Esperion Therapeutics, Inc. The primary endpoint was relative risk reduction in major adverse cardiovascular events (MACE-4*) ➤ Comprehensive data will be presented at a key medical congress * Composite of the time to first cardiovascular death, nonfatal myocardial infarction, non-fatal stroke, or coronary revascularization 15

View entire presentation